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Abstract
Foxp3, a 47-kDa transcription factor, is necessary for the function of CD4+CD25+ regulatory T cells (Tregs), with an essential
role in the control of self-reactive T cells and in preventing autoimmunity. Activation of Tregs by TCR engagement results in
upregulation of Foxp3 expression, followed by its rapid nuclear transport and binding to chromatin. Here, we identify three
distinct Foxp3 domains that contribute to nuclear transport. The first domain (Domain 1) comprises the C-terminal 12 amino
acids. The second domain (Domain 2) is located immediately N-terminal to the forkhead domain (FHD), recently reported to
be a binding site for the runt-related transcription factor 1/acute myeloid leukemia 1 (Runx1/AML1). The third domain
(Domain 3) is located within the N-terminal first 51 amino acids. Unlike the known nuclear localization signals (NLSs), none
of these three regions are rich in basic residues and do not bear any similarity to known monopartite or bipartite NLSs that
have one or more clusters of basic amino acids. The basic arginine-lysine-lysine-arginine (RKKR) sequence, located 12-aa
from the C-terminal end of Foxp3 was previously reported to be a nuclear localization signal (NLS) for several proteins,
including for a GFP-Foxp3 hybrid. Evidence is provided here that in the full-length native Foxp3 RKKR does not function as
an NLS. The data reported in this study indicates that Foxp3 achieves nuclear transport by binding to other nuclear factors
and co-transporting with them to the nucleus.
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Introduction
CD4+CD25+ regulatory T cells (Tregs) play a critical role in
establishing immune tolerance and in prevention of autoimmunity.
Foxp3, a DNA-binding protein expressed by natural Tregs, is
necessary for Treg function. Ectopic expression of Foxp3 in
CD4+CD25- cells is sufficient for their conversion to a Treg
phenotype [1,2]. In mice, a frame-shift mutation in the Foxp3
forkhead domain (FHD) results in the loss of the DNA-binding
residues, leading to the Scurfy phenotype and lethal autoimmunity
[1,3]. In humans, multiple mutations in the Foxp3 gene can lead to
IPEX (immunodysregulation, polyendocrinopathy, enteropathy,
X-linked), a syndrome that is similar to Scurfy, with multi-organ
lymphocytic infiltration, lympadenopathy, exfoliative dermatitis,
hepatosplenomegaly and autoantibodies [4–6].
Like other members of the FoxP subfamily, Foxp3 has zinc-finger
and leucine-zipper domains. Foxp3 can form homo-dimers and
tetramers, and can associate with Foxp1 [7]. The leucine-zipper
domain of Foxp3 plays an essential role in the formation of higher
order structures [7]. Foxp3 can exist as part of a large functional
complex of ,600 kDa, together with histone deacetylases, histone
acetyltransferases and Runx1/AML1) [8,9]. Its association with
several transcription factors has been reported, including retinoid-
related orphan receptors -a and -ct( R O R - a and ROR-ct) [10,11],
nuclear factor of activated T cells (NFAT), nuclear factor of kappa
light polypeptide gene enhancer in B-cells (NF-kB) and Activator
protein (AP-1) [12–14]. The expression and function of Foxp3 is
regulated by acetylation [8]. Foxp3 is processed by proteolytic
cleavage events at two RXXR motifs (
48RDLR
51 and
414RKKR
417),
resulting in different forms that are functionally distinct [15].
Binding of Foxp3 to different promoters can lead to acetylation
of histones at some promoters (GITR, CD25 and CTLA-4) and
to deacetylation at others (IL-2 and IFN-c) [16]. Foxp3 is a
multifunctional protein, and consistent with its opposite effects on
promoter acetylation, it functions as a transcriptional repressor or
an activator [13,16].
Although Foxp3 has been intensively studied, little is known
about how it translocates from cytoplasm into the nucleus. The
mechanism of Foxp3 nuclear import was thus the focus of this
study. WT and Foxp3 mutants were retrovirally expressed in
CD4+ cells and after transduction, the rate of Foxp3 nuclear
translocation was determined by Western blot analysis of the
subcellular fractions. The results show that three separate regions
contribute to nuclear transport of Foxp3.
Results
The Basic RKKR Sequence Does Not Function as a Classic
NLS in the Full-Length Foxp3
RKKR was reported to be a NLS for several proteins, including
for the GFP-Foxp3 hybrid [17–20]. To determine whether it
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7890functions as a NLS in native Foxp3, several constructs were made
in which single or multiple residues of
414RKKR
417 were replaced
with unrelated amino acids. The nuclear transport properties of
WT and mutant Foxp3s were then determined in CD4+ cells
using retroviral expression, followed by Western blot analysis of
the subcellular fractions. The replacement of the second arginine
in the first mutant with an unrelated amino acid did not alter its
nuclear transport kinetics (mutant A; RKKR to RKKX; replaced
residues underlined) (Fig. 1). Subsequent replacement of both of
the arginines (RKKRt oXKKX) (mutant B) or both of the lysines
(RKKR to RXXR) (mutant C) similarly did not have any effect,
indicating RKKR does not function as a NLS in the full-length
protein (Fig. 1).
Foxp3 was recently shown to be processed immediately after
two RXXR motifs [15]. N-terminal cleavage of Foxp3 after
RDLR (
48RDLRQS
52) generates N-cleaved Foxp3, C-terminal
cleavage after RKKR (
414RKKRQS
418) generates C-cleaved
Foxp3, and cleavage at both ends generates N&C-cleaved (double-
cleaved) form of the protein. The C-cleaved form (417-aa), ending
with RKKR, is only 12-aa shorter than the full-length 429-aa
Foxp3. To determine whether RKKR in short C-cleaved Foxp3
serves as a NLS, a construct that encodes Foxp3 mimicking the
C-cleaved form (missing residues 418–429) was generated (referred
to as C-short, designated as RKKRN where N indicates engineered
stop codon). In a separate construct, the terminal residues of
C-short (RKKRN) were replaced with unrelated amino acids
(XXXXN). Retroviral expression showed, while the C-short Foxp3
(RKKRN) could transport to the nucleus at a similar rate as the full-
length protein, the C-short mutant (XXXXN) had a slower nuclear
translocation rate (Fig. 1). This data contrasts the data obtained
from full-length Foxp3 mutants where replacement of RKKR
residues were found not to alter the kinetics of nuclear transport
(Fig. 1, mutants A–C). The results show, unlike in full-length
Foxp3, the terminal RKKR in C-short Foxp3 can function as a
NLS. A likely possibility is that in the full-length Foxp3 RKKR is
masked by the 12-aa tail whereas in C-short Foxp3 RKKR is
exposed and recognized by the NLS-mediated nuclear import
machinery. However, a biological role for RKKR as a NLS is
unlikely since full-length Foxp3 is already in the nucleus when the
C-terminal cleavage takes place and the 12-aa tail is released [15].
The C-Terminal 12-Amino Acids of Foxp3 Contribute to
Nuclear Transport (Domain 1)
The differences in the nuclear translocation rates of full-length
Foxp3 mutants (RKKX--, XKKX-- and RXXR--) and the C-
short mutant (XXXXN) suggested that the C-terminal tail may
have a role in nuclear transport of Foxp3 (Fig. 1). To determine
whether this is the case, a construct encoding a full-length Foxp3
mutant (XXXX--) was made by attaching a DNA-fragment
encoding the 12-aa tail sequences to the C-terminal end of the C-
Figure 1. Comparison of the nuclear translocation abilities of WT Foxp3 and Foxp3 mutants. A. Schematic diagram showing the
approximate locations of the zinc-finger (ZF), leucine-zipper (LZ) and the forkhead domain (FHD) in the full-length WT mouse Foxp3. Vertical arrows
indicate sites of proteolytic cleavage. The amino acid sequences RPP and RKKR shown in the schematic diagrams represent the first and the last
residues of the FHD. Mutant residues in mut A, mut B, mut C, and C-short mutant Foxp3 are indicated with an X. The lower diagram shows the
structure of C-short Foxp3 lacking the terminal 12-aa tail. This engineered Foxp3 mimics the natural C-cleaved form of the protein, a result of
proteolytic processing at
414RKKRQS
418. B. Western blot showing nuclear and cytoplasmic distribution of WT Foxp3 (RKKR--), mut A (RKKX--), mut B
(XKKX--), mut C (RXXR--), C-short Foxp3 (RKKRN) and C-short Foxp3 mutant (XXXXN). Lanes 11 and 12 (inside the frame), corresponding to C-short
mutant (XXXXN), reveal an impaired rate of nuclear translocation. CD4+ cells were harvested 24 hr after retroviral transduction and subcellular
fractions obtained. Mutant residues on all the Western blot figures are shown with X and highlighted in grey. N indicates engineered ends and double
dashes (--) indicate the 12-aa tail. Following treatment with the Foxp3 mAbFJK-16s, the membrane was treated with SP1 and Actin antibodies to
determine the efficiency of subcellular fractionation. The second species migrating slightly slower then Actin in lanes 1-12 is Foxp3. Foxp3 signal was
generated along with the Actin signal due to previous treatment of the membrane with Foxp3 antibody. N, nuclear extract; C, cytoplasmic extract.
The N and C designations are used in all the figures. C. Western blot showing equal Foxp3 expression in total extracts obtained from samples shown
in B. SP1 signal was used to determine loading.
doi:10.1371/journal.pone.0007890.g001
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distribution of the short and the full-length Foxp3 mutants
(XXXXN and XXXX--) showed the attachment of the 12-aa tail
dramatically improved the rate nuclear translocation (Fig. 2, lanes
5 and 6 versus lanes 7 and 8). The result indicates the C-terminal
12-aa tail (14-aa in the human), referred to as Domain 1,
contribute to nuclear transport of Foxp3 (Fig. 2).
Sequences Immediately N-Terminal to the FHD
Contribute to Nuclear Transport of Foxp3 (Domain 2)
The removal of Domain 1 (C-terminal tail) from Foxp3 only
slows down the rate of nuclear translocation, and transport is
complete by day 5 following retroviral transduction (Fig. 3),
indicating additional region(s) in Foxp3 also contribute to its
nuclear transport. To identify these region(s), a search was initiated
and the C-short Foxp3 mutant (XXXXN) which does not have the
RKKR sequence and the C-terminal Domain 1 was further
mutated at multiple sites. Mutations in several regions of Foxp3
did not alter the kinetics of nuclear translocation (data not shown).
However, a region located immediately N-terminal to the FHD
having two histidine-asparagine-methionine (HNM) repeats was
found to be important. The HNM repeats, conserved between
mouse and human, are separated by a 5-aa spacer region, and the
16
th lysine residue of Foxp3 is located within this spacer. The two
constructs that pin-pointed this region have partially overlapping
mutations. The rate of nuclear translocation of the two mutants
(Fig. 4B, mutants 1 and 2; mutant residues boxed) were compared
to C-short Foxp3 mutant (XXXXN), used as control. While 50% of
the control was found in the nucleus at 24-hrs after retroviral
transduction, both mutants 1 and 2, having mutations at
approximately the same location, were significantly impaired in
their nuclear translocation ability (Fig. 4C, lanes 3–6). Thus, the
region immediately N-terminal to the FHD contributes to nuclear
transport of Foxp3 and is referred to as Domain 2. It should be
noted that the 16
th lysine of Foxp3 (residue 332) plays a critical
role since when this lysine is kept intact, nuclear transport is only
minimally affected (data not shown). This region that includes the
16
th lysine was recently reported to be essential for binding of
Foxp3 to Runx1 transcription factor [9].
N-Terminal Sequences of Foxp3 (the First 51-aa)
Contribute to Nuclear Transport (Domain 3)
Earlier experiments comparing the nuclear translocation rates
of full-length Foxp3 and an engineered Foxp3 that mimics the N-
terminally cleaved form (N-short Foxp3: 378-aa) showed the lack
of the N-terminal 51-aa residues reduce the rate of nuclear
translocation (Fig. 5B). The role of the N-terminal domain was
further probed by studying the nuclear transport of a Foxp3
mutant that lacks the N-terminal 51-aa, Domain 1 and lacks a
functional Domain 2. The results show this mutant protein missing
Domains 1, 2, and 3 is found almost exclusively in the cytoplasm
(Fig. 6B, lanes 7 and 8). The detection of trace levels of this mutant
in the nuclear extract (Fig. 6B, lane 7) is likely due to cross-
contamination of nuclear and cytoplasmic fractions during the
separation process. Hence, the first 51-aa of Foxp3, referred to as
Domain 3, represents the third region that contributes to Foxp3
nuclear transport.
Discussion
This study identifies three domains in Foxp3 that participate in
its nuclear translocation. These three domains are located at the
C-terminal end (Domain 1), immediately N-terminal to the FHD
(Domain 2) and at the N-terminal end of Foxp3 (Domain 3)
(Fig. 7). None of these domains are rich in basic residues and do
not have similarities to previously described monopartite or
bipartite NLSs [21–23]. The central domain (Domain 2), located
at the N-terminal side of FHD, was recently reported to be a
binding site for the transcription factor Runx1 [9]. Thus, it is likely
that the other two domains of Foxp3 also interact with nuclear
factors that help transport Foxp3 to the nucleus. A similar type of
nuclear transport, by ‘‘piggy-backing’’, has been described for
Figure 2. The C-terminal 12-aa residues (Domain 1) contribute
to nuclear localization. A. Schematic diagram of WT Foxp3 (RKKR--),
C-short mutant (XXXXN) and full-length mutant (XXXX--). Domain 1 that
corresponds to the C-terminal 12-aa tail and necessary for efficient
translocation of Foxp3 is marked. B. Western blot showing increased
nuclear translocation of Foxp3 following the addition of tail residues
(lanes 5–8; 212-aa versus +12-aa). CD4+ cells were harvested 24 hr after
retroviral transduction. Lower panels, SP1 (nuclear) and Actin (cyto-
plasmic) controls.
doi:10.1371/journal.pone.0007890.g002
Figure 3. Foxp3 missing Domain 1 and the RKKR residues can
fully translocate to the nucleus over time. A. Schematic diagram
of WT Foxp3 (RKKR--) and C-short Foxp3 mutant (XXXXN). B. Western
blot showing nuclear and cytoplasmic distribution of WT-Foxp3 and C-
short Foxp3 mutant at Day 1 and Day 5 following retroviral
transduction. Lower panels, SP1 and Actin controls.
doi:10.1371/journal.pone.0007890.g003
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nucleus by binding to Cyclin F which has multiple functional
NLSs [24].
Processing of Foxp3 results in N-terminally or C-terminally
cleaved forms of the protein. It is noteworthy that the nuclear
factors that dock onto Domains 1 and 3 would likely be released
together with the N- or C-terminal ends following proteolytic
cleavage. Whether Foxp3 is N-terminally or C-terminally cleaved
may determine which factor(s) remain associated with it. Such a
mechanism can give Foxp3 the ability to associate with different
factors in order to achieve its multifunctional role in transcrip-
tional regulation. The existence of a similar mechanism, the
interaction of human Foxp3 with the transcription factors RORa
and RORct, has recently been described. Full-length human
Foxp3 (Foxp3a) can bind both RORa and RORct, whereas the
shorter Foxp3b isoform, lacking the exon 2 residues that interact
with RORa and RORct, cannot [10,11].
Proteolytic cleavage of Foxp3 at the C-terminal RXXR motif
(
414RKKRQS
418), located only 12-aa from the C-terminal end,
leads to a slightly shorter protein but affects Treg function
dramatically [15]. RKKR is reported to be a NLS for several
proteins, including for a GFP-Foxp3 hybrid [17–20]. This study
undertakes a detailed mutational analysis of native full-length
Foxp3 to determine whether RKKR functions as a NLS. The
results show, RKKR does not function as a NLS in the native full-
length protein, possibly due to being masked by the neighboring
C-terminal 12 amino acid tail. It is noted that the tail sequence is
moderately rich in proline residues, known to introduce kinks and
Figure 4. Sequences immediately N-terminal to the FHD (Domain 2) contribute to nuclear translocation of Foxp3. A. Schematic
diagram of C-short Foxp3 mutant (XXXXN). Additional mutations were introduced in order to identify the second domain that contributes to Foxp3
nuclear translocation. The arrow marks the location of Domain 2 and the converging lines lead to the sequences shown in B. B. Mutations in Domain
2 that impair the nuclear translocation ability of Foxp3. Mutant residues in mut 1, mut 2 of this study and of Ono (detailed sequence shown in Ono et
al. [9]) are boxed. The 16
th lysine in the control C-short mutant is underlined. C. Western blot showing the impaired nuclear translocation ability of
mutants 1 and 2 (lanes 3, 4 and 5, 6 versus lanes 7, 8). CD4+ cells were harvested one day after retroviral transduction. WT Foxp3 (lanes 1, 2) is from
the same experiment but analyzed on a separate blot. Lower panels, SP1 and Actin controls. Abbreviation: mut designates mutant.
doi:10.1371/journal.pone.0007890.g004
Figure 5. N-terminal 51-aa of Foxp3 (Domain 3) contribute to
its nuclear translocation. A. Schematic diagram of WT Foxp3 and of
Foxp3 missing the N-terminal 51-aa (N-short). B. Western blot showing
the nuclear and cytoplasmic distribution of WT and N-short Foxp3. The
reduced size of N-short Foxp3 (41-kDa) in lanes 3 and 4 is due to the
absence of N-terminal 51-aa. CD4+ cells were harvested 20 hr after
transduction. Lower panels, SP1 and Actin controls.
doi:10.1371/journal.pone.0007890.g005
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tail of mouse Foxp3 and 4 prolines in the 14-aa tail of the human
Foxp3. Thus, proline induced turns in the 12-aa tail may result in
concealing RKKR and preventing it from functioning in NLS-
mediated nuclear import. In addition, the fact that no RKKR
mutations in IPEX patients have been linked to a deficiency in
nuclear localization also argues against a NLS role for RKKR.
The discrepancy between the results presented here and of Lopes
et al., on the role of the RKKR as a NLS, can be explained by
their use of a GFP-Foxp3 hybrid instead of the native protein [20].
GFP has a considerable size (26 kDa) which can affect folding of
the Foxp3 portion. That even minor deviations from the native
structure may have profound functional consequences is supported
by the fact that the C-terminal processing of Foxp3, and
subsequent deletion of the C-terminal tail which is considered to
be a non-critical region for Foxp3, dramatically affects the overall
function of the protein [15].
Foxp3 forms a large complex (,600 kDa) with several factors,
including the histone acetyltransferase Tip60, histone deacetylase
HDAC7, RORa, RORct, Runx1 and NFAT [8,27]. However,
neither Domain 1 nor 3 of Foxp3 have been implicated in binding
to these factors. Identification of the factors that interact with these
domains will not only facilitate our understanding of how Foxp3
achieves its nuclear transport to regulate the expression of target
genes, but may lead to development of therapies that modify Treg
function.
Materials and Methods
Animals
FemaleC57BL/6 mice(6–8 weeks old) werepurchased from The
Jackson Laboratory (Bar Harbor, ME). All studies were performed
with a protocol approved by the institutional animal care and use
committee of The Children’s Hospital of Philadelphia.
Antibodies
Anti-mouse Foxp3 mAb FJK-16s (ebioscience; catalog number
14-5773-82), SP1 and Actin antibodies (Santa Cruz Biotechnol-
ogy; catalog numbers sc-59 and sc-1615) were used for Western
blots.
cDNA Cloning and Mutagenesis
mFoxp3 cDNA was amplified from thymus with Foxp3-specific
forward and reverse primers (Integrated DNA Technologies) and
Figure 6. Contribution of Domains 1, 2 and 3 to nuclear translocation. A. Schematic diagram of WT Foxp3 and of Foxp3 mutant that lacks
the N-terminal 51-aa, Domain 1 and a functional Domain 2 (marked with white slanted lines). Vertical arrows indicate sites of proteolytic cleavage. B.
Nuclear and cytoplasmic distribution of Foxp3 mutants (XXXX): missing only Domain 1 (lanes 3 and 4); missing Domains 1 and 2 (lanes 5 and 6);
missing Domains 1, 2 and 3 (lanes 7 and 8). CD4+ cells were harvested 24 hr after transduction. Lower panels, SP1 and Actin controls. C. Western blot
showing equal Foxp3 expression in total extracts obtained from samples shown in B. SP1 signal was used to determine loading. Abbreviation: Domn
designates Domain.
doi:10.1371/journal.pone.0007890.g006
Figure 7. Domains 1, 2 and 3 of Foxp3. Schematic diagram
showing the locations of the N-terminal and C-terminal cleavage sites
(between residues 51 and 52, and 417 and 418). The approximate
locations of Domains 1, 2 and 3 that contribute to nuclear transport of
Foxp3 are indicated. Grey oval structures designate factors that bind to
these three domains and help nuclear translocation of Foxp3.
doi:10.1371/journal.pone.0007890.g007
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number 211188-5). The mutations were introduced with a
QuikChange site II-directed mutagenesis kit (Stratagene; catalog
number 200523-5). For equal expression, all constructs had the
same length of Foxp3 cDNA but were engineered to encode
different Foxp3 forms. The different Foxp3 forms were generated
either by insertion of a stop codon (for C-short Foxp3) or an
initiation codon (encoding methionine; for N-short Foxp3) in the
correct locations of the cDNA. Construction of the plasmid that
encodes N-short Foxp3 required multiple mutagenesis steps to
abolish the natural ATG and another ATG 25-base downstream
of the first one, to prevent chain initiation at undesired locations.
After sequence confirmation, fragments were recloned to murine
stem cell virus (MSCV)-based Minr-1 vector for retroviral
expression.
Retroviral Expression
Retroviruses were generated by co-transfection of WT or mutant
Foxp3 (in Minr-1 vector) with pCLeco (Invitrogen) helper plasmid
into the 293T-based Phoenix ecotropic packaging cell line, using
Lipofectamine 2000 Reagent (Invitrogen; catalog number 52887).
Viruscontainingsupernatantwascollected andused toinfectpurified
CD4+ cells. Prior to infection with the retrovirus, CD4+ T cells were
isolated by magnetic sorting, activated with PMA (3 ng/ml),
i o n o m y c i n( 1m M )a n dI L - 2( 5U / m l )f o r2 4h r ,w a s h e d ,a n d
transduced using the 48 hr viral supernatants obtained from
transfected Phoenix cells [16].
Nuclear and Cytoplasmic Extraction and Western Blots
Following retroviral transduction, CD4+ cells were expanded
for either 20 hr, 24 hr or 5 days before subcellular fractionation
[28]. Proteins were separated by 14% SDS-PAGE, blotted onto
PVDF membrane, probed with the primary Ab followed by
secondary Ab-HRP. Signal was obtained with the Luminol
reagent (Santa Cruz Biotech; catalog number sc-2048) and
recorded onto Kodak MR Film. Prior to Actin antibody
treatment, some blots were stripped with the Restore Western
Blot Stripping Buffer (Pierce; catalog number 21059) to remove
the Foxp3 antibody from the membrane.
Acknowledgments
The authors would like thank Guanghui Ge for technical assistance. EO ¨
would like to thank Dr. Robert Snapka (Ohio State University) for scientific
discussions.
Author Contributions
Conceived and designed the experiments: EO. Performed the experiments:
EO. Analyzed the data: EO. Contributed reagents/materials/analysis
tools: WH EO. Wrote the paper: EO.
References
1. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the
development and function of CD4+CD25+ regulatory T cells. Nat Immunol
4: 330–336.
2. Allan SE, Alstad AN, Merindol N, Crellin NK, Amendola M, et al. (2008)
Generation of potent and stable human CD4+ T regulatory cells by activation-
independent expression of FOXP3. Mol Ther 16: 194–202.
3. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, et al. (2001)
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal
lymphoproliferative disorder of the scurfy mouse. Nat Genet 27: 68–73.
4. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, et al. (2001) The
immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome
(IPEX) is caused by mutations of FOXP3. Nat Genet 27: 20–21.
5. Wildin RS, Smyk-Pearson S, Filipovich AH (2002) Clinical and molecular
features of the immunodysregulation, polyendocrinopathy, enteropathy, X
linked (IPEX) syndrome. J Med Genet 39: 537–545.
6. Gambineri E, Torgerson TR, Ochs HD (2003) Immune dysregulation,
polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome
of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of
T-cell homeostasis. Curr Opin Rheumatol 15: 430–435.
7. Li B, Samanta A, Song X, Iacono KT, Brennan P, et al. (2007) FOXP3 is a
homo-oligomer and a component of a supramolecular regulatory complex
disabled in the human XLAAD/IPEX autoimmune disease. Int Immunol 19:
825–835.
8. Li B, Samanta A, Song X, Iacono KT, Bembas K, et al. (2007) FOXP3
interactions with histone acetyltransferase and class II histone deacetylases are
required for repression. Proc Natl Acad Sci U S A 104: 4571–4576.
9. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, et al. (2007) Foxp3
controls regulatory T-cell function by interacting with AML1/Runx1. Nature
446: 685–689.
10. Du J, Huang C, Zhou B, Ziegler SF (2008) Isoform-specific inhibition of ROR
alpha-mediated transcriptional activation by human FOXP3. J Immunol 180:
4785–4792.
11. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, et al. (2008) TGF-beta-
induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgam-
mat function. Nature 453: 236–240.
12. Bettelli E, Dastrange M, Oukka M (2005) Foxp3 interacts with nuclear factor of
activated T cells and NF-kappa B to repress cytokine gene expression and
effector functions of T helper cells. Proc Natl Acad Sci U S A 102: 5138–5143.
13. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, et al. (2006) FOXP3
controls regulatory T cell function through cooperation with NFAT. Cell 126:
375–387.
14. Lee SM, Gao B, Fang D (2008) FoxP3 maintains Treg unresponsiveness by
selectively inhibiting the promoter DNA-binding activity of AP-1. Blood 111:
3599–3606.
15. de Zoeten EF, Lee I, Wang L, Chen C, Ge G, et al. (2009) Foxp3 processing by
proprotein convertases and control of regulatory T cell function. J Biol Chem
284: 5709–5716.
16. Chen C, Rowell EA, Thomas RM, Hancock WW, Wells AD (2006)
Transcriptional regulation by Foxp3 is associated with direct promoter
occupancy and modulation of histone acetylation. J Biol Chem 281:
36828–36834.
17. Kirito K, Fox N, Kaushansky K (2004) Thrombopoietin induces HOXA9
nuclear transport in immature hematopoietic cells: potential mechanism by
which the hormone favorably affects hematopoietic stem cells. Mol Cell Biol 24:
6751–6762.
18. Mikami Y, Hori T, Kimura H, Fukagawa T (2005) The functional region of
CENP-H interacts with the Nuf2 complex that localizes to centromere during
mitosis. Mol Cell Biol 25: 1958–1970.
19. Song JH, Waataja JJ, Martemyanov KA (2006) Subcellular targeting of RGS9-2
is controlled by multiple molecular determinants on its membrane anchor,
R7BP. J Biol Chem 281: 15361–15369.
20. Lopes JE, Torgerson TR, Schubert LA, Anover SD, Ocheltree ED, et al. (2006)
Analysis of FOXP3 reveals multiple domains required for its function as a
transcriptional repressor. J Immunol 177: 3133–3142.
21. Kalderon D, Richardson WD, Markham AF, Smith AE (1984) Sequence
requirements for nuclear location of simian virus 40 large-T antigen. Nature
311: 33–38.
22. Moreland RB, Langevin GL, Singer RH, Garcea RL, Hereford LM (1987)
Amino acid sequences that determine the nuclear localization of yeast histone
2B. Mol Cell Biol 7: 4048–4057.
23. Kleinschmidt JA, Seiter A (1988) Identification of domains involved in nuclear
uptake and histone binding of protein N1 of Xenopus laevis. Embo J 7:
1605–1614.
24. Kong M, Barnes EA, Ollendorff V, Donoghue DJ (2000) Cyclin F regulates the
nuclear localization of cyclin B1 through a cyclin-cyclin interaction. Embo J 19
(2000) 1378-1388.
25. Nilsson I, von Heijne G (1998) Breaking the camel’s back: proline-induced turns
in a model transmembrane helix. J Mol Biol 284: 1185–1189.
26. Tieleman DP, Shrivastava IH, Ulmschneider MR, Sansom MS (2001) Proline-
induced hinges in transmembrane helices: possible roles in ion channel gating.
Proteins 44: 63–72.
27. Zhou Z, Song X, Li B, Greene MI (2008) FOXP3 and its partners: structural
and biochemical insights into the regulation of FOXP3 activity. Immunol Res
42: 19–28.
28. Schreiber E, Matthias P, Muller MM, Schaffner W (1989) Rapid detection of
octamer binding proteins with ‘mini-extracts’, prepared from a small number of
cells. Nucleic Acids Res 17: 6419.
Nuclear Translocation of Foxp3
PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7890